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Zinc finger protein X-linked (ZFX) is a zinc finger protein of Zfy family, which is highly conserved in vertebrates. This transcrip-
tional regulator is not only highly expressed in embryonic stem cells (ESC) and hematopoietic stem cells, but is also upregu-
lated in a number of human cancers where it is functional related to cell proliferation and survival. Hepatocellular carcinoma
(HCC) is highly aggressive cancer that commonly resistant to most chemotherapies and displays stemness characteristics. In
this study, we examined the expression of ZFX in HCC and its possible functional implications in liver tumorigenesis. Quantita-
tive RT-PCR analysis showed common overexpressions of ZFX in 51.8% HCC tumors when compared with their adjacent non-
malignant liver (n 5 43/83; p 5 0.004). Inline with the pluripotency role of ZFX, we found silencing of ZFX readily inhibited
self-renewal capability (p 5 0.0022), colony formation ability (p < 0.0001) and cell proliferation (p < 0.0001) through G0/G1
cell cycle arrest of HCC cells (p 5 0.0038). In addition, suppression of ZFX sensitized HCC cells to chemotherapeutic agent cis-
platin (p < 0.0001). Further investigations suggested that ZFX bind on the promoter of two important mediators, namely
Nanog and SOX-2, activating their expressions in HCC (p < 0.0001). Moreover, in vivo xenograft study demonstrated that over-
expression of ZFX would promote the tumor growth (p 5 0.031). Taken together, our results show, for the first time, com-
monly overexpressions of ZFX in HCC, where it likely contributes to the stemness and pluripotent behavior of this highly
malignant cancer.
Hepatocellular carcinoma (HCC), which accounts for 80–
90% of all liver cancers, is the ﬁfth most common cancer and
the third leading cause of cancer-related deaths worldwide.1
HCC is an aggressive cancer with a high mortality rate; often
due to being diagnosed at a late stage when curative therapies
are least effective.2 Moreover, most HCC patients show dis-
ease recurrence that rapidly progresses to advanced stages. It
is general believed that the presence of cancer stem-like fea-
tures is responsible for chemoresistance and recurrence of
HCC.3–7 ZFX is a zinc ﬁnger protein of the Zfy family that is
highly conserved among vertebrates. It is a transcriptional
factor encoded on the mammalian X chromosome and con-
tains an acidic transcriptional activation domain, a nuclear
localization sequence and a DNA binding domain.8,9 Despite
elevated levels are detected in pluripotent embryonic stem
cells (ESCs) and hematopoietic stem cells (HSCs) where it is
required for maintenance of self-renewal ability,8 ZFX is also
found to be frequently overexpressed in a number of human
cancers, including esophageal carcinoma, gastric cancer, pros-
tate cancer, and glioma.10–13 Common cancer stemness char-
acteristics, including colony-forming ability, acquisition of
drug resistance, cell survival, and cancer metastasis have been
further proposed to be induced from ZFX in these cancers.
In HCC, the role of ZFX however remains unexplored. The
present study hence aims to examine the expression and
functional effects of ZFX in the liver tumorigenesis.
Here, we report, for the ﬁrst time, common upregulation
of ZFX in HCC tissues (51.8%). In functional analysis, we
showed knockdown of ZFX could induce G0/G1 phase cell
cycle arrest and reduce cell proliferation and colony forma-
tion abilities of HCC cells. Also, depletion of ZFX could sup-
press the self-renewal ability and sensitized HCC cells to
chemotherapeutic drug cisplatin. Vice versa, ectopic expres-
sion of ZFX would promote cell proliferation, and colony for-
mation ability of HCC cells. In addition, ZFX could bind on
promoter of transcriptional factors regulatory network
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including SOX-2 and Nanog and inﬂuence their expressions.
Moreover, the overexpression of ZFX would promote in vivo
tumor growth. The identiﬁcation and functional characteriza-
tion of ZFX in HCC provides new insights into the
stemness-associated features of HCC and the possible use of
ZFX as a therapeutic target.
Material and Methods
Patients
Tumorous liver tissues were collected from 83 patients who
underwent curative surgery for HCC at Prince of Wales Hos-
pital, Hong Kong. Informed consent was obtained from each
patient, and the study protocol was approved by the Clinical
Research Ethics Committee of the Chinese University of
Hong Kong. A diagnosis of HCC was conﬁrmed on histo-
logic examination by pathologists. The demographic informa-
tion of HCC patient cohort was shown in Supporting
Information Table 1. Six normal livers were used in this
study. Three of them were purchased from commercial com-
panies (Ambion and Calbiochem), while remaining three
were liver transplantation.
Cell culture
The in-housed established human HCC cell lines HKCI-10,
HKCI-C2, and HKCI-8 were maintained as described previ-
ously.14 In brief, these cell lines were cultured in RPMI 1640
glutamax medium (Invitrogen) supplemented with 10% fetal
bovine serum. The immortalized normal liver cell line L02
was cultured in DMEM medium (Invitrogen) supplemented
with 10% fetal bovine serum.
RNA extraction, cDNA synthesis, and quantitative RT-PCR
(qRT-PCR)
Total RNA from cells and tissues were isolated by TRIzol
reagent (Invitrogen, Carlsbad, CA) and treated with RQ1
Rnase-free Dnase (Promega Corporation, Madison, WI) to
eliminate genomic DNA carryover. First-strand cDNA syn-
thesized from random hexamer was subjected to TaqMan
assay for target genes in Universal PCR Mix (ABI, Foster
City, CA). The emission intensity was detected by iCycler IQ
detection system using ﬂuorophore FAM490 (Bio-Rad, Her-
cules, CA). Threshold cycles were averaged from triplicate
reactions. To adjust for variations in starting template, gene
expression was normalized against 18S rRNA. Fold change
relative to mean value obtained from 6 normal liver controls
was determined by 22DDCt. A relative gene expression of two-
fold or more was considered up-regulation.
Western blot analysis
Protein lysates were resolved on 8% sodium dodecyl sulfate–
polyacrylamide gel electrophoresis (SDS-PAGE) and trans-
ferred electrophoretically on to polyvinylidene ﬂuoride mem-
brane. After blocking for nonspeciﬁc binding, blots were
incubated with speciﬁed antibodies against ZFX, SOX-2,
Nanog (1:1000; Cell Signaling), or glyceraldehyde-3-
phosphate dehydrogenase (1:25,000; Chemicon). After incu-
bation with secondary conjugated to horseradish peroxidase,
protein bands were visualized using enhanced chemilumines-
cence detection (GE Healthcare, Piscataway, NJ).
Lentiviral packaging and transduction
HEK293FT cells were transfected with packaging plasmids
pCMV-VSV-G, pRSV-Rev, and pMDLg/pRRE along with
pLKO.1-NS Ctrl or pLKO.1-hZFX shRNA (Sigma) using
FUGENE transfection reagent (Roche). After 48 hr post-
transfection, viral supernatant was precipitated with PEG-it
Virus Precipitation Solution in 1:4 ratio to produce concen-
trated viral stock. HKCI-10 and HKCI-C2 were plated 1 day
before transduction. After 48 hr post-transduction, cells were
selected in medium containing 2 mg/ml puromycin for 10
days.
Stable expression of ZFX in HCC cell line HKCI-8
HKCI-8 was transfected with pCMV6-empty vector or
pCMV6-ZFX (Origene) containing the neomycin resistance
gene by using LipofectamineTM 2000 transfection reagent
(Invitrogen). After 48 hr post-transfection, cells were selected
in medium with 500 mg/ml of Geneticin (Life Technologies)
for 3 weeks. The overexpression of ZFX was conﬁrmed by
qPCR analysis.
Cell cycle analysis by propidium iodide
Stable transfected cells (3 3 105) were harvested when
reached approximately 80% conﬂuence. The cells were trypsi-
nized, washed with PBS and ﬁxed in 3 ml ice-cold 70% etha-
nol at 220C overnight. Fixed cells were pelleted by
centrifugation at 1,000g for 5 min. Then the cells were
washed by PBS twice and stained with 1ml staining solution
containing 50 mg/ml propidium iodide and 0.5 mg/ml RNase
A for 30 min and subjected to ﬂow cytometric analysis. Flow
What’s new?
Zinc Finger Protein X-linked gene (ZFX) is a member of Zfy family of transcriptional regulators that is often highly expressed in
embryonic and hematopoietic stem cells. In this study, the authors find that ZFX is commonly overexpressed in hepatocellular
carcinoma, where it promotes the expression of stem cell-associated transcription factors such as Nanog and SOX-2. These
findings may shed new light on chemoresistance and frequent recurrence of hepatocellular carcinomas, symptoms attributed
to stemness and pluripotent behavior of this cancer.
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cytometric study was performed by BD FACSCaliburTM using
CellQuest software. The average value of G0/G1, S, and G2/
M phase were averaged from at least three independent
experiments.
Cell proliferation assay
Stable transfected cells (1 3 103) seeded on a 96-well micro-
titer plate with 8 replicate wells were allowed to incubate for
different time interval from days 1 to 7. Cell proliferation
was measured by MTT assay. Colorimetric product formed
will be measured at absorbance 570 nm every day for 7 con-
secutive days.
EdU cell proliferation assay
DNA replication was measured using a Click-it EdU Flow
Cytometry Assay kit, which is based on incorporation of the
thymidine analogue 5-ethynyl-20-deoxyuridine (EdU) into
DNA during replication (Invitrogen). The stable transfected
cells (3 3 105) were cultured in complete medium with 10
mM EdU for 2 hr before harvested and washed with 3 ml of
1% BSA in PBS. Then cells were ﬁxed with 100 ml of Click-
iT ﬁxative and incubated for 15 min at room temperature.
After washed once with 3 ml of 1% BSA in PBS, the cells
were resuspended in 100 ml of 1X Click-iT saponin-based
permeabilization and wash reagent. Then cells were added
with 0.5 ml of Click-iT reaction cocktail. After washed and
resuspended in 500 ml of 1X Click-iT saponin-based perme-
abilization and wash reagent, cells were analyzed on BD
FACSCaliburTM. The percentages of different ﬂuorescent cells
were analyzed using WinMDI Ver.2.9.
Colony formation assay
Stable transfected cells were seeded in 6-well tissue culture
plates (200 cells per well). After an incubation period of 7
days, the medium was decanted and each well was washed
twice with PBS. The cells were stained with 1% crystal violet
(in 100% methanol) for 15 min, followed by detaining. Colo-
nies (more than >20 cells/colony) were counted.
Single-cell clonogenic assay
To assess self-renewal in vitro, single-cell clonogenic assay
was done as described previously.15 In brief, a single-cell was
seeded into 96-well plates (1 cell per well), and cultured in
10% fetal bovine serum-containing medium. After 1 day
incubation, wells containing no cells or more than one cell
were excluded. Wells containing only one cell were marked
and observed daily under microscope. Cell clones were
counted after 7 days when a clone reached 20 cells.
In vitro cytotoxicity assay
Stable transfected cells (5 3 103) seeded on a 96-well micro-
titer plate with 8 replicate wells were allowed to incubate for
48 hr with the treatment of anticancer drug cisplatin (20
mM). After incubation, cell viability was assessed utilizing the
thiazolyl blue tetrazolium bromide (MTT) assay. Colorimetric
complex formed dissolved by DMSO was determined for
absorbance at 570 nm.
ChIP-PCR
Chromatin immunoprecipitation (ChIP) was performed as
previously described,16 with slightly modiﬁcation. Brieﬂy, 2
days after transient transfected with ZFX-Flag plasmid, L02
cells were ﬁxed with 1% formaldehyde, and then lysed in
RIPA buffer containing 13 Protease Inhibitor Cocktail.
Cross-linked chromatins were fragmented to approximately
600 bp by sonication. After centrifugation, sonicated chroma-
tin was diluted tenfold with ChIP dilution buffer and pre-
cleared with protein G-sepharose for 1 h at 4C, then
incubated with anti-Flag antibody or IgG control at 4C
overnight. After immunoprecipitation, protein G-sepharose
beads were used to collect immunoprecipitated complex. The
beads were washed once with low salt buffer, once with high
salt buffer, once with LiCl washing buffer and twice with TE
buffer. Then, protein–DNA complexes were eluted with Elu-
tion buffer, followed by cross-linking reversal and protease K
treatment. Finally, DNA was puriﬁed by QIAGEN PCR puri-
ﬁcation kit and eluted with 50 ml sterile water. Real-time
ChIP-PCR by SYBR Green-based detection method was per-
formed to detect putative ZFX targets. Primers designed to
cover potential ZFX binding sites were listed in Supporting
Information Table 2. Each reaction contained equal amount
of ChIP or input DNA.
In vivo xenograft study
1 3 107 of ZFX-stable expressed HKCI-8 cells were resus-
pended in 100 ll PBS and were injected on the dorsal surface
of the 7 weeks old nude mice (control: left side, ZFX: right
side). Tumor volumes were monitored every 5 days over the
course of treatment by caliper measurement of the length
and width and calculated using the formula of (width)2 3
length/2. Mice were sacriﬁced after 3 weeks of treatments
then the tumors were removed and measured.
Statistical analysis
Expression of ZFX in HCC tumors was compared with adja-
cent nontumoral livers by paired Student’s t test and to nor-
mal livers by Mann–Whitney test. Statistical correlations of
ZFX expression and clinicopathological parameters were car-
ried out by unpaired Student’s t test. The effect of ZFX in
functional studies was compared using the paired Student’s t
test. p < 0.05 was considered statistically signiﬁcant. All sta-
tistical analyses were performed using GraphPad Prism 3.02
(GraphPad Software Inc., San Diego, CA).
Results
ZFX is commonly overexpressed in human HCC
The expression of ZFX in HCC was determined by qRT-PCR
in a cohort of 83 HCC tumors (T) and paired adjacent non-
tumoral livers (TN), and 6 normal liver tissues (NL). Quanti-
tation of ZFX levels showed signiﬁcant up-regulation in HCC
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tumors as compared to normal livers (Mann–Whitney test p
5 0.036), and in 43 tumors when compared with their adja-
cent nonmalignant livers (51.8%) (paired Student’s t test p 5
0.0041) (Fig. 1a). In ﬁve cases that showed increased ZFX
mRNA expression, Western blot also concurred in indicating
higher protein level of ZFX in tumors compared to matching
nonmalignant liver (Fig. 1b). We also attempted to correlate
expression of ZFX in tumoral tissues with clinicopathological
features of patients. Correlative analysis did not suggest sta-
tistical signiﬁcance between ZFX expression and parameters,
including gender, age, HBV status, histology grade, number
of lesions, macrovascular invasion, and microvascular inva-
sion. However, advanced Stage III tumors exhibited higher
ZFX expressions as compared to early stages I and II HCCs
(unpaired Student’s t test p 5 0.0348) (Fig. 1c), suggesting
ZFX expression is related to tumor staging. On further segre-
gation of HCC tumors arising from a cirrhotic or noncir-
rhotic background, we found a signiﬁcantly higher expression
of ZFX in cirrhosis-associated tumors compared to their non-
malignant counterpart (paired Student’s t test p 5 0.0099).
Since tumor adjacent cirrhotic liver is often considered a pre-
malignant lesion of HCC, our ﬁnding would suggest ZFX
plays a role in predisposing the risk of HCC development
(Fig. 1d).
Knockdown of ZFX induces G0/G1 cell cycle arrest in HCC
cells
To gain insight into functional role of increased ZFX expres-
sion in HCC, two HCC cell lines (HKCI-10 and HKCI-C2)
with elevated ZFX expression (p 5 0.0091) (Fig. 2a) were
used to establish ZFX-deﬁcient stable clones (clone 1: shZFX-
C1, clone 2: shZFX-C2) by lentiviral transfection. The knock-
down efﬁciency of ZFX was determined by qRT-PCR (p <
0.0001) and western blotting (Fig. 2b). In cell cycle analysis
by PI staining, we found the signiﬁcant increase in G0/G1
cell population but decrease in both S and G2/M population.
The reduction of S 1 G2/G1 ratio after knockdown of ZFX
suggested that depletion of ZFX would induce the G0/G1 cell
cycle arrest in HCC (p < 0.0016) (Fig. 2c).
ZFX is required for HCC cell growth and proliferation
In addition, the deﬁciency of ZFX signiﬁcantly reduced the
in-vitro proliferation of HCC in MTT assay (p < 0.0001)
(Fig. 3a) and decreased the amount of proliferating cell pop-
ulation in EdU cell proliferation assay (HKCI-10, shZFX-C1:
p 5 0.0038; shZFX-C2: p < 0.0001) (HKCI-C2: p < 0.0001)
(Fig. 3b). Also, fewer in number and smaller-sized colonies
were formed in ZFX-depleted cells from colony formation
assay (p < 0.0001) (Fig. 3c). Vice versa, ectopic expression of
ZFX could promote cell proliferation (p < 0.0001) (Support-
ing Information Fig. 1a) and colony formation ability (p <
0.0001) (Supporting Information Fig. 1b) of HCC cells. Our
results suggested that ZFX is required for the in vitro prolif-
eration and growth of HCC.
ZFX induces stem-like cell properties of HCC cells
Since ZFX plays key roles in the maintenance of pluripo-
tency, we next investigated the potential role of ZFX on regu-
lation of stem-like cell characteristics in HCC. Reasoning that
self-renewal and drug resistance are two important features
of stemness behavior, we hence assayed for the effect ZFX on
these two properties. Indeed, we found that suppression of
ZFX could impede the self-renewal ability of HCC cells,
which was reﬂected by fewer colonies and smaller sizes
formed in single-cell clonogenic assay in ZFX-depleted
HKCI-10 (p < 0.0001) and HKCI-C2 (p 5 0.0022) (Fig. 4a).
In addition, we found knockdown of ZFX could sensitize
HCC cells to anticancer drug cisplatin, which was reﬂected
by the deduction of IC50 from 16.86 1 1.067 mg/ml (shCtrl)
to 6.73 1 1.1 mg/ml (shZFX-C1), and 7.03 1 1.12 mg/ml
Figure 1. Overexpression of ZFX in HCC. (a) qRT-PCR showed the
upregulation of ZFX in HCC tumoral tissues (n 5 83) (*p 5 0.036;
ns, not significant) as compared to normal livers (n 5 6) and in 43
tumors when compared with their adjacent nonmalignant livers (T/
TN>2) (51.8%) (**p 5 0.0041). (NL: normal liver tissues, TN:
paired adjacent nontumoral livers, T: HCC tumors). (b) Western blot
analysis demonstrated the upregulation of ZFX protein level in HCC
tumors as compared to their adjacent nonmalignant livers. (c) qRT-
PCR analysis showed a higher expression of ZFX in stage III tumors
as compared to stages I and II HCCs (*p 5 0.0348). (d) qRT-PCR
showed a significant higher expression of ZFX in cirrhotic HCC
tumoral tissues as compared to noncirrhotic HCC tumoral tissues
(**p 5 0.0099; ns, not significant).
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(shZFX-C2) in ZFX-depleted HCC cells (p < 0.0001) (Fig.
4b). These ﬁndings evidently demonstrated that ZFX confers
stem-like properties to HCC cells.
ZFX influences expression of SOX-2 and Nanog in HCC
Transcriptional factors regulatory network including SOX-2,
Nanog, OCT-4, and Notch1 have been reported to support
and control a set of target genes that play important roles in
ESC pluripotency.17,18 We then investigated whether ZFX
inﬂuences the expression of transcriptional factors including
SOX-2, OCT4, Nanog, and Notch1. We found a signiﬁcant
reduction in the mRNA (p < 0.0001) and protein expressions
of SOX-2 and Nanog (Figs. 5a and 5b) under the depletion
of ZFX. However, no apparent change in the expression of
OCT-4 and Notch1 was suggested (Supporting Information
Fig. 2). In addition, there was signiﬁcant induction in mRNA
of SOX-2 and Nanog after ectopic expression of ZFX in
HCC cells (p < 0.0001) (Fig. 5c). Moreover, putative ZFX
binding sites on SOX2 and Nanog promoters were predicted
by JASPAR online database (http://www.jaspar.genereg.net/
cgi-bin/jaspar_db.pl) with relative proﬁle score threshold at
85%. Totally six putative sites on SOX2 and three potential
Figure 2. Depletion of ZFX induces G0/G1 cell cycle arrest of HCC cells. (a) HCC cell lines, HKCI-10, and HKCI-C2 showed a high expression
of ZFX as compared to normal livers tissues (**p 5 0.0091). The mRNA expression level of ZFX in normal livers, HKCI-10 and HKCI-C2 was
determined by qRT-PCR. (b) Knockdown of ZFX in HCC cell lines. qRT-PCR (upper panel) and western blotting (lower panel) demonstrated
the knockdown efficiency of ZFX in ZFX-depleted HKCI-10 (***p < 0.0001) and HKCI-C2 (***p < 0.0001). (c) Depletion of ZFX induced G0/
G1 cell cycle arrest. Propidium iodide (PI) staining demonstrated the induction of G0/G1 cell population but decrease in S and G2/M popu-
lation (left panel). Right panel showed the reduction of S 1 G2/G1 ratio after knockdown of ZFX in HKCI-10 (***p < 0.0001) and HKCI-C2
(**p 5 0.0016).
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sites on Nanog had been identiﬁed within their 2k promoter
regions (Fig. 5d).18 To conﬁrm whether ZFX bind to pro-
moter regions of SOX-2 and Nanog, we designed different
sets of primers (Supporting Information Table 2) that cov-
ered the putative binding sites of ZFX. Using ChIP-PCR, we
found that the ZFX-pull down DNA enriched the binding
site on the promoter regions of SOX-2 (p < 0.012) (Fig. 5e).
Although a signiﬁcant enrichment on the promoter regions
of Nanog was not suggested, qPCR analysis demonstrated a
positive correlation between the expression of ZFX and
Nanog in the 83 pairs of HCC primary cases (p 5 0.031)
(Fig. 5f). Our data highlights the likelihood of Nanog and
SOX-2 as downstream targets of ZFX.
ZFX promotes in vivo tumor growth
Finally, the tumorigenicity of overexpressed ZFX was exam-
ined using nude mouse model. Our result demonstrated that
overexpression of ZFX in HCC cells could promote the
Figure 3. Knockdown of ZFX suppresses in vitro proliferation of HCC cells. The cell proliferation of ZFX-depleted cell was measured by (a)
MTT assay (***p < 0.0001) and (b) EdU cell proliferation assay [left panel showed the population of nonproliferating cell (P1) and prolifer-
ating cell (P2). Right panel showed the change in percentage of nonproliferating cell and proliferating cell under ZFX-depletion (**p 5
0.0038, ***p < 0.0001)]. (c) Colony formation assay showed the reduction of colony formation ability after knockdown of ZFX (***p <
0.0001). [Color figure can be viewed in the online issue, which is available at wileyonlinelibrary.com.]
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growth of xenografts, suggesting ZFX is required for the in
vivo growth of HCC tumor (p 5 0.031) (Fig. 6).
Discussion
Recent studies on ZFX have suggested an important role for
this transcription factor in tumorigenesis. Here, we report for
the ﬁrst time the presence of common ZFX up-regulations in
HCC and demonstrated the contribution of ZFX in the main-
tenance of stem-like characteristics of HCC cells. Of interest,
we showed a novel association of ZFX overexpression with
HCC arising from liver cirrhosis. Currently, about 70–90% of
HCC developed from a cirrhotic liver, of which the major
etiologic insults included viral hepatitis infections, excessive
alcohol consumptions and metabolic syndrome. The ﬁnding
of elevated ZFX in cirrhosis-associated HCC might imply on
its potential contribution in cancer development from the
putative premalignant lesion of liver cirrhosis. We also
showed depletion of ZFX could signiﬁcantly reduce the self-
renewal ability of HCC cells. Knockdown of ZFX could also
sensitize HCC cells to cytotoxic drug cisplatin, which would
in turn suggest ZFX as a potential therapeutic target for
more efﬁcacious treatment.
There are growing evidences on different cancer stem cell
hypotheses, one of which states that primary tumors are
organized in a hierarchy of heterogeneous cell populations
and maintained by cancer cells that possess “stem-like” char-
acteristics including unlimited cell division, chemotherapy
resistant, and self-renewal in an undifferentiated state.19–21
However, this hypothesis of tumor-initiating stem-like cells
(TISCs) has much been argued by many scientists who
believed that the stem cell-like properties are not limited to a
“subpopulation” of cancer cells, and may be a more general-
ized phenomenon that can be found in the bulk of tumor. In
line with the later, our data would infer that stemness
Figure 4. ZFX confers stemness features in HCC cells. (a) Depletion of ZFX reduced the single cell colony formation ability in HCC cells,
HKCI-10 (***p < 0.0001), and HKCI-C2 (**p 5 0.0022). Single-cell clonogenic assay (left panel) was used to determine single cell colony
formation ability, cell clones reached >20 cells were considered as cell colonies. Representative micrographs (right panel) of HKCI-10 and
HKCI-C2 cell colonies in single-cell clonogenic assay. (b) Knockdown of ZFX sensitized HCC to chemotherapeutic drug cisplatin (***p <
0.0001). Cell viability of HCC in response to chemotherapeutic drug was determined by MTT assay after treatment of cisplatin (0–100 mM)
for 48 h. Left panel was sigmoidal curve showing the percentage of cell viability in response to cisplatin treatment. Right panel showed the
deduction of IC50 of cisplatin in ZFX-depleted HCC cells (***p < 0.0001). [Color figure can be viewed in the online issue, which is available
at wileyonlinelibrary.com.]
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features augmented by ZFX can be seen in the major popula-
tion of HCC cells as suppression of ZFX readily resulted in
an extensive reduction in cell growth and self-renewal ability.
Moreover, the overexpression of ZFX in HCC could promote
both in vitro HCC cell proliferation and in vivo growth of
xenograft.
In deﬁning the downstream effectors of ZFX in HCC, we
explored the inﬂuence of ZFX on the expression of stem-like
Figure 5. ZFX influences the expressions of transcriptional factors SOX-2 and Nanog in HCC. (a) Decreased in mRNA expressions of SOX-2
and Nanog in ZFX-depleted HCC cells were determined by qRT-PCR (***p < 0.0001). (b) The reduction of SOX-2 and Nanog protein expres-
sions level in ZFX-depleted HCC were determined by western blotting. (c) qRT-PCR demonstrated the induction of Nanog and SOX-2 after
overexpression of ZFX (***p < 0.0001). (d) JASPAR analysis demonstrated six putative ZFX binding sites on SOX-2 promoter and three
putative ZFX binding sites on Nanog promoter (highlighted in blue). Red boxes are the primer designed for ChIP-PCR analysis (Supporting
Information Table 2). (e) ChIP-PCR analysis of ZFX occupancy in the SOX-2 and Nanog promoters of L02 cells (*p 5 0.012, **p 5 0.007). (f)
qRT-PCR analysis demonstrated the positive correlation between mRNA expression of ZFX and Nanog in 83 pairs of primary HCC tumoral
tissues and adjacent nonmalignant livers (*p 5 0.031). [Color figure can be viewed in the online issue, which is available at
wileyonlinelibrary.com.]
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promoting genes, including Nanog, Oct-4, Notch1, and SOX-
2. Although no apparent changes in the expression of Oct-4
and Notch1 was detected, we found a prominent effect of
ZFX on the level of SOX-2 and Nanog expressions. Also,
result of ChIP-PCR analysis suggested ZFX would bind on
the promoter of SOX-2. Recent studies have indicated that
co-expression of SOX-2 and Nanog can reprogram somatic
cells into pluripotent embryonic stem-like cells,22,23 suggest-
ing that combined expression of stem cell-associated factors
in cells with oncogenes could also induce an undifferentiated
state in these cells. Furthermore, Nanog and SOX-2 have fur-
ther been shown to play important roles in the progression
of cancers,24–26 which might enforce the expression of ZFX,
Nanog and SOX-2 in promoting the tumorigenic potentials
of HCC cells. Moreover, it was reported that Nanog expres-
sion could signiﬁcantly increase chemo-resistant oral squa-
mous carcinoma cells and pancreatic cancer cells.27,28 Since
our data showed that expression of ZFX positively correlated
with expression of Nanog, it is plausible that the mechanism
underlying drug sensitization in ZFX-depleted HCC cells
may be due to the downregulation of Nanog.
In conclusion, this study demonstrates that ZFX is com-
monly overexpressed in HCC where it confers stemness
properties and chemoresistance. Further investigations into
the signaling network of ZFX may provide new insights and
therapeutic potentials for treatment of HCC.
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